ProCE Banner Activity

Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Slideset Download

Get up to date on individualizing therapy with BTK inhibitors for the management of chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma by considering patient characteristics and the unique safety profile of available BTK inhibitors.

Released: October 11, 2023

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca